Core Viewpoint - Changjiang Life Science Technology (00775) expects to report a shareholder loss of approximately HKD 150 million for the six months ending June 30, 2025, compared to a profit of HKD 1 million in the same period of 2024, primarily due to the company's decision to increase R&D investment [1] Group 1 - The expected shareholder loss of HKD 150 million marks a significant shift from the previous year's profit of HKD 1 million [1] - The company's operational performance has remained stable during the reporting period and up to the date of this announcement [1]

Core Viewpoint - Changjiang Life Science Technology (00775) expects to report a shareholder loss of approximately HKD 150 million for the six months ending June 30, 2025, compared to a profit of HKD 1 million in the same period of 2024, primarily due to the company's decision to increase R&D investment [1] Group 1 - The company anticipates a significant shift from profit to loss in its financial performance [1] - The expected loss is attributed to increased investments in research and development [1] - Overall, the company's operations have remained stable during the reporting period and up to the date of the announcement [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或 完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚賴該 等內容而引致的任何損失承擔任何責任。 （於開曼群島註冊成立之有限公司） （股份代號：0775） 盈利警告 本公告乃根據香港聯合交易所有限公司證券上市規則（「上市規則」）第 13.09(2)(a)條及證券 及期貨條例（香港法例第 571 章）第 XIVA 部項下之內幕消息條文（定義見上市規則）刊發。 長江生命科技集團有限公司（「本公司」，連同其附屬公司，統稱「本集團」）董事會（「董 事會」）謹此通知本公司股東（「股東」），根據本集團截至二零二五年六月三十日止六個月 （「報告期間」）未經審核綜合管理賬目（「管理賬目」）之初步審閱，以及董事會目前所得之 資料，本集團預期報告期間錄得約港幣一億五千萬元股東應佔虧損，對比二零二四年同期，股東 應佔溢利為港幣一百萬元。是次應佔溢利轉盈為虧乃歸因於本公司早前計劃增加研發投資之決定。 整體而言，本集團的營運於報告期間及截至本公告日期一直維持穩定。本公司將於二零二五年 八月十二日發佈之中期業績公告中披露更多詳 ...

格隆汇7月31日丨长江生命科技(00775.HK)宣布，公司将于2025年8月12日（星期二）于香港举行董事会 会议，以（其中包括）批准刊发公司及其附属公司截至2025年6月30日止六个月的中期业绩，以及考虑 派发中期股息。 ...

(於開曼群島註冊成立之有限公司) （股份代號：0775） 董事會召開日期 香港交易及結算所有限公司及香港聯合交易所有限公司對本文件的內容概不負責，對 其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本文件全部或任何部分 內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 香港，二零二五年七月三十一日 於本文件日期，本公司執行董事為李澤鉅先生（主席）、甘慶林先生、葉德銓先生、 余英才先生 、 Lance Richard Lee Yuen 先 生 及 杜 健 明 醫 生 ； 非 執 行 董 事 為 Peter Peace Tulloch 先生、郭李綺華女士（獨立非執行董事）、關啟昌先生（獨立非執行 董事）、Paul Joseph Tighe 先生（獨立非執行董事）及羅弼士先生（獨立非執行董事）。 長江生命科技集團有限公司（「本公司」）之董事會（「董事會」）謹此宣佈，本公司將於 二零二五年八月十二日（星期二）於香港舉行董事會會議，以（其中包括）批准刊發本公司及 其附屬公司截至二零二五年六月三十日止六個月之中期業績，以及考慮派發中期股息。 承董事會命 長江生命科技集團有限公司 公司秘書 楊逸芝 ...

Core Viewpoint - The biotechnology sector is characterized by high returns and high risks, with successful products potentially surpassing the value of many listed infrastructure and real estate companies [1] Group 1: Company Strategy and Research - The company is currently engaged in multiple cancer vaccine research projects, including the TROP2 cancer vaccine, which has shown significant tumor growth inhibition in preclinical studies [1] - The TROP2 protein is overexpressed in various cancers, including triple-negative breast cancer, lung cancer, and colorectal cancer, with the company's vaccine demonstrating 100% tumor growth inhibition in mouse models [1] - The company estimates that it will take approximately 24-30 months to initiate Phase I/II clinical trials for the TROP2 vaccine [1] Group 2: Asset Management and Financial Strategy - The company considers its health products and agriculture-related businesses as important, generating stable cash flow to support research and development [1] - The company will continue to evaluate strategic options to enhance shareholder value and optimize its business structure, with any significant developments to be disclosed to the market [1] - There are currently no announcements regarding the potential spin-off of the biopharmaceutical division for a Hong Kong listing, and the company is assessing strategic opportunities to improve shareholder value [2] - The company has not announced any plans for fundraising through share placements or convertible bonds to support research and development [2]

Group 1 - Jiangsu Life Science Technology (00775.HK) recently announced promising early results from preclinical laboratory tests of its novel cancer vaccine targeting trophoblast cell surface antigen 2 (TROP2) [1] - The TROP2 vaccine has shown significant tumor growth inhibition in preclinical studies, with four out of five studies demonstrating 100% tumor growth suppression and one study showing approximately 80% suppression in over 170 mice [1] - The TROP2 vaccine is expected to become the first curative therapy for high-incidence cancers in Asia, addressing urgent clinical needs and potentially covering multiple cancer types such as lung and pancreatic cancer [1] Group 2 - The company has multiple clinical-stage medical research projects and its R&D product line is considered severely undervalued, with potential for value release and substantial performance contributions [2] - The company reported a nearly 60% year-on-year increase in clinical trial and laboratory expenses, reaching HKD 161 million in 2024, indicating a strong commitment to R&D [2] - The company is exploring various strategic options, including strategic partnerships, joint ventures, business spin-offs, and mergers, to maximize shareholder value and enhance its capital acquisition channels [2]

Group 1 - The Hang Seng Index rose by 0.12%, gaining 26 points to close at 21,998 points, while the Hang Seng Tech Index increased by 0.81% with a trading volume of HKD 97.3 billion in the morning session [1] - Ant Group plans to invest HKD 28.14 billion to acquire a controlling stake in Yau Tat Securities, leading to a surge in Alibaba-related stocks, with Yau Tat Securities rising by 20% and Alibaba Health increasing by 6% [1] - Meituan-W saw a morning increase of 3.82%, as institutions expect the competition landscape in the food delivery industry to remain stable, suggesting long-term value release for the platform [1] - Longjiang Life Science (00775) rose over 9% after showcasing various cancer vaccine data at AACR 2025 [1] - Horizon Robotics-W (09660) also increased by over 9% following a strategic partnership with Denso, with institutions indicating a positive outlook for the industry chain [1] Group 2 - Zai Lab (09911) increased by 6.48%, driven by significant growth in social business revenue in Q1, and the company is exploring overseas acquisition opportunities [2] - Lao Pu Gold (06181) rose over 6%, as institutions noted that fixed-price gold products benefit from the rising gold prices [3] - Shangmei Co., Ltd. (02145) surged by 8%, reaching a new historical high, with institutions optimistic about the long-term growth potential of the beauty care sector [4] - Tigermed (03347) fell over 2% post-earnings, with Q1 net profit attributable to shareholders decreasing by nearly 30%, although there is still room for improvement in gross margin [4] - Qingdao Beer Co., Ltd. (00168) dropped by 3.7% post-earnings, despite a 7.08% year-on-year increase in net profit for Q1 [4] - Longyuan Power (00916) declined over 6% post-earnings, with Q1 net profit attributable to shareholders decreasing by 21.82% and wind power segment revenue down by 1.89% [4] - Rongchang Bio (09995) fell by 8.21% post-earnings, despite nearly 60% year-on-year revenue growth in Q1, with losses narrowing to CNY 254 million [4]

Core Insights - The company, Changjiang Life Sciences (00775), will present the latest preclinical research data on its cancer vaccine at the AACR 2025 Annual Meeting in Chicago [1][2] - The cancer vaccine targets several proteins, including Preferentially Expressed Antigen in Melanoma (PRAME), programmed cell death-ligand 1 (PD-L1), B7 homolog 3 (B7-H3), and Claudin 6 [1][2] - The company is satisfied with the preclinical efficacy results of the cancer vaccines targeting these proteins and aims to advance them to clinical stages [2] Research and Development - PRAME is a protein highly expressed in melanoma, liver cancer, and blood cancers [1] - PD-L1 is a crucial immune checkpoint protein that inhibits T cell activation in the tumor microenvironment [1] - B7-H3 is another immune checkpoint protein that regulates T cell responses and is often overexpressed in cancers [2] - Claudin 6 is a tight junction protein that regulates epithelial barrier integrity and is overexpressed in breast cancer, lung cancer, and endometrial cancer [2] AI-Driven Vaccine Design - The company will showcase two panels at the AACR 2025 Annual Meeting in collaboration with research partners, highlighting an AI-driven platform for designing cancer vaccines [2] - The use of the AI platform is expected to enhance the immunogenicity and efficacy of the designed vaccines [2] Clinical Trials - The company is accelerating its cancer vaccine research, with multiple therapeutic cancer vaccines at various stages, including clinical and preclinical phases [2] - The cancer vaccine seviprotimut-L is currently in the final research phase, being tested as an adjuvant therapy for melanoma patients post-surgery [2]

Financial Performance - For the fiscal year ending December 31, 2024, the company reported a loss attributable to shareholders of HKD 126.6 million, a decrease of HKD 143.9 million compared to a profit of HKD 17.3 million in 2023[7]. - The profit attributable to shareholders for 2023 was HKD 17.25 million, a significant decrease from HKD 131.96 million in 2022[95]. - Total revenue for the year ended December 31, 2023, was HKD 5,322.7 million, a slight increase from HKD 5,275.6 million in 2022[95]. - The fair value of the vineyard investment portfolio recorded a post-tax impairment of HKD 44 million in 2023, negatively impacting profits compared to the previous year[68]. - The group maintained a net debt to total equity ratio of approximately 58.36% as of December 31, 2024[97]. Research and Development - The company's investment in research and development increased from HKD 145.9 million in 2023 to HKD 254.1 million in 2024, representing an annual increase of HKD 102.8 million[11]. - The therapeutic cancer vaccine seviprotimut-L is currently in the final research phase, undergoing trials as an adjuvant therapy for melanoma patients post-surgery[10]. - Halneuron®, a non-opioid pain relief drug based on tetrodotoxin, is currently undergoing a Phase II clinical trial for chemotherapy-induced neuropathic pain[29]. - The company is expanding its therapeutic cancer vaccine portfolio, with promising laboratory results for vaccines targeting KRAS and PD-L1 presented at the AACR annual meeting[39]. - Jiangsu Life Science Technology is actively exploring the development of an AI-driven cancer vaccine discovery platform in collaboration with Crystal Technology, aiming to enhance the discovery and development process of new cancer vaccines[40]. Strategic Initiatives - The company is actively exploring innovative fields, including the use of artificial intelligence to accelerate the discovery and development of new cancer vaccines[12]. - The merger of WEX Pharmaceuticals with Virios Therapeutics to form Dogwood Therapeutics aims to expedite the development of Halneuron® for treating chemotherapy-induced neuropathic pain[9]. - The company plans to launch new formulations and implement innovative marketing strategies to capture the growing demand for health products post-COVID-19[15]. - The company has made strategic investments in liquid biopsy testing projects to provide non-invasive and cost-effective cancer detection solutions[13]. - The company is focused on developing unique products to meet consumer health needs, particularly in areas such as sleep, joint pain, immunity, and energy[62]. Environmental and Sustainability Efforts - The company is committed to sustainable development, as evidenced by the establishment of a Sustainability Committee[115]. - The company has acquired government grazing leases and rights to over 350,000 hectares of farmland in Australia for regenerative agriculture and carbon sequestration purposes, equivalent to more than three times the area of Hong Kong[133]. - Vitaquest has transitioned to using 100% renewable energy in 2024, reflecting the company's commitment to sustainable practices in health product manufacturing[134]. - The company is focused on identifying and addressing challenges and opportunities related to climate change, aiming to mitigate climate-related impacts and adapt to new environments[134]. - The company is committed to improving its environmental performance and has established policies and procedures to manage its environmental footprint[134]. Corporate Governance and Leadership - The company has a strong board of directors with members holding significant positions in various listed companies, enhancing corporate governance and strategic oversight[111][113][114][115]. - The company is focused on expanding its market presence and enhancing its product offerings through strategic appointments and experienced leadership[109][110]. - The leadership team has a strong educational background, with many members holding advanced degrees in relevant fields, contributing to informed decision-making[109][110][115]. - The company is committed to maintaining high standards of corporate governance and compliance through its experienced board members[116][121]. - The board includes independent directors with extensive backgrounds in finance, governance, and international relations, ensuring diverse perspectives in decision-making[113][115]. Market and Operational Strategies - Australian Agribusiness is implementing cost-cutting measures and adjusting product mix to alleviate the impact of material price fluctuations and high market inventory[18]. - The company is focused on enhancing operational efficiency, expanding sales, and improving productivity to promote internal growth[92]. - The company is implementing strategic operational measures to improve financial performance amid challenges such as high inflation and rising energy costs[86]. - The company has appointed a new independent non-executive director, Mr. Lo, who has extensive experience in finance and corporate governance[116]. - The company has a diverse executive team with members holding advanced degrees in business administration and law, enhancing its strategic capabilities[118][120]. Shareholder Information - As of December 31, 2024, the group’s major shareholder, Li Ka-shing, holds approximately 2,838,009,715 shares, representing 29.52% of total shares[146]. - Major shareholders include Gold Rainbow (BVI) Limited and its affiliates, holding approximately 4,355,634,570 shares, representing 45.31% of total shares[150]. - The company’s public float is approximately 24.99552%, which is below the minimum requirement of 25% as per listing rules[179]. - The board does not recommend the distribution of a final dividend for the fiscal year ending December 31, 2024[138]. - The total annual caps for continuing connected transactions I are set at HKD 100,000,000 for 2024, HKD 110,000,000 for 2025, and HKD 130,000,000 for 2026[164].